Teladoc Stock Jumps 27% on Day It Reported Third-Quarter Results

Teladoc Health (NYSE: TDOC) shares rose 26.9% on Thursday, Oct. 29, 2026, closing at $8.73 from a previous close of $6.88. The S&P 500 ETF (SPY) fell 0.38% over the same session, and volume was 5.6 times normal. The company did not state a cause for the move in the filing, and no analyst action or other news explains it directly.

Results released the day before

Teladoc filed an 8-K on Oct. 28, 2026 at 4:04 p.m. ET, furnishing a press release on its third-quarter 2026 results. Revenue was $605.1 million, down 3% year over year. Net loss narrowed to $26.9 million, or $0.15 per share, from $49.5 million, or $0.28 per share, a year earlier. Adjusted EBITDA rose 14% to $79.4 million.

Segment performance

Integrated Care revenue rose 2% to $398.5 million, with an adjusted EBITDA margin of 18.8%. BetterHelp revenue fell 13% to $206.6 million, though insurance revenue exceeded the company's expectations, according to the release. Chief Executive Chuck Divita said results were near the upper end of guidance for consolidated revenue and above the range for adjusted EBITDA.

Outlook

For the fourth quarter of 2026, Teladoc expects revenue of $569 million to $615 million and adjusted EBITDA of $74 million to $100 million. For full-year 2026, it expects revenue of $2,395 million to $2,441 million and free cash flow of $135 million to $165 million.

Filing context

Teladoc also filed a 10-Q on Oct. 29, 2026 at 10:30 a.m. ET. Cash and cash equivalents were $849.9 million at Sept. 30, 2026.